Literature DB >> 19321460

Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers.

Hedok Lee1, Hanna Rosenmann, Joab Chapman, Peter B Kingsley, Chen Hoffmann, Oren S Cohen, Esther Kahana, Amos D Korczyn, Isak Prohovnik.   

Abstract

Human prion diseases present substantial scientific and public health challenges. They are unique in being sporadic, infectious and inherited, and their pathogen is distinct from all other pathogens in lacking nucleic acids. Despite progress in understanding the molecular structure of prions, their initial cerebral pathophysiology and the loci of cerebral injury are poorly understood. As part of a large prospective study, we analysed early diffusion MRI scans of 14 patients with the E200K genetic form of Creutzfeldt-Jakob Disease, 20 healthy carriers of this mutation that causes the disease and 20 controls without the mutation from the same families. Cerebral diffusion was quantified by the Apparent Diffusion Coefficient, and analysed by voxel-wise statistical parametric mapping technique. Compared to the mutation-negative controls, diffusion was significantly reduced in a thalamic-striatal network, comprising the putamen and mediodorsal, ventrolateral and pulvinar thalamic nuclei, in both the patients and the healthy mutation carriers. With disease onset, these diffusion reductions intensified, but did not spread to other areas. The caudate nucleus was reduced only after symptomatic onset. These findings indicate that cerebral diffusion reductions can be detected early in the course of Creutzfeldt-Jakob Disease, and years before symptomatic onset in mutation carriers, in a distinct subcortical network. We suggest that this network is centrally involved in the pathogenesis of Creutzfeldt-Jakob Disease, and its anatomical connections are sufficient to account for the common symptoms of this disease. Further, we suggest that the abnormalities in healthy mutation-carrying subjects may reflect the accumulation of abnormal prion protein and/or associated vacuolation at this time, temporally close to disease onset.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19321460      PMCID: PMC2759334          DOI: 10.1093/brain/awp064

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  36 in total

1.  Creutzfeldt-Jakob disease profile in patients homozygous for the PRNP E200K mutation.

Authors:  E S Simon; E Kahana; J Chapman; T A Treves; R Gabizon; H Rosenmann; N Zilber; A D Korczyn
Journal:  Ann Neurol       Date:  2000-02       Impact factor: 10.422

2.  Cerebellar projections to the prefrontal cortex of the primate.

Authors:  F A Middleton; P L Strick
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

3.  High incidence of subclinical infection of lymphoid tissues in scrapie-affected sheep flocks.

Authors:  Gudmundur Georgsson; Jona Adalheidur Adolfsdottir; Astridur Palsdottir; Einar Jorundsson; Sigurdur Sigurdarson; Stefania Thorgeirsdottir
Journal:  Arch Virol       Date:  2008-01-29       Impact factor: 2.574

Review 4.  Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy.

Authors:  P Brown
Journal:  Haemophilia       Date:  2007-12       Impact factor: 4.287

5.  Progression of prion infectivity in asymptomatic cattle after oral bovine spongiform encephalopathy challenge.

Authors:  Juan Carlos Espinosa; Mónica Morales; Joaquín Castilla; Mark Rogers; Juan María Torres
Journal:  J Gen Virol       Date:  2007-04       Impact factor: 3.891

6.  Prion protein with an E200K mutation displays properties similar to those of the cellular isoform PrP(C).

Authors:  H Rosenmann; G Talmor; M Halimi; A Yanai; R Gabizon; Z Meiner
Journal:  J Neurochem       Date:  2001-03       Impact factor: 5.372

7.  Insomnia associated with thalamic involvement in E200K Creutzfeldt-Jakob disease.

Authors:  Ana Lia Taratuto; P Piccardo; E G Reich; S G Chen; G Sevlever; M Schultz; A A Luzzi; M Rugiero; G Abecasis; M Endelman; A M Garcia; S Capellari; Z Xie; E Lugaresi; P Gambetti; S R Dlouhy; B Ghetti
Journal:  Neurology       Date:  2002-02-12       Impact factor: 9.910

8.  Neuropathological and molecular comparison between clinical and asymptomatic bovine spongiform encephalopathy cases.

Authors:  Silvia Sisó; Marcus G Doherr; Catherine Botteron; Rosemarie Fatzer; Andreas Zurbriggen; Marc Vandevelde; Torsten Seuberlich
Journal:  Acta Neuropathol       Date:  2007-09-01       Impact factor: 17.088

9.  The imaging appearance of Creutzfeldt-Jakob disease caused by the E200K mutation.

Authors:  Robert K Fulbright; Peter B Kingsley; Xiaodong Guo; Chen Hoffmann; Esther Kahana; Joab C Chapman; Isak Prohovnik
Journal:  Magn Reson Imaging       Date:  2006-09-07       Impact factor: 2.546

10.  MRI detection of the cerebellar syndrome in Creutzfeldt-Jakob disease.

Authors:  Oren S Cohen; Chen Hoffmann; Hedok Lee; Joab Chapman; Robert K Fulbright; Isak Prohovnik
Journal:  Cerebellum       Date:  2009-05-01       Impact factor: 3.847

View more
  18 in total

1.  Pruritus in familial Creutzfeldt-Jakob disease: a common symptom associated with central nervous system pathology.

Authors:  Oren S Cohen; Joab Chapman; Hedok Lee; Zeev Nitsan; Shmuel Appel; Chen Hoffman; Hanna Rosenmann; Amos D Korczyn; Isak Prohovnik
Journal:  J Neurol       Date:  2010-08-21       Impact factor: 4.849

2.  Brain-water diffusion coefficients reflect the severity of inherited prion disease.

Authors:  H Hyare; S Wroe; D Siddique; T Webb; N C Fox; J Stevens; J Collinge; T Yousry; J S Thornton
Journal:  Neurology       Date:  2010-02-23       Impact factor: 9.910

3.  Characterization of sleep disorders in patients with E200K familial Creutzfeldt-Jakob disease.

Authors:  Oren S Cohen; Joab Chapman; Amos D Korczyn; Naama Warman-Alaluf; Yael Orlev; Gili Givaty; Zeev Nitsan; Shmuel Appel; Hanna Rosenmann; Esther Kahana; Dalia Shechter-Amir
Journal:  J Neurol       Date:  2014-12-02       Impact factor: 4.849

4.  Familial Creutzfeldt-Jakob disease with the E200K mutation: longitudinal neuroimaging from asymptomatic to symptomatic CJD.

Authors:  Oren S Cohen; Joab Chapman; Amos D Korczyn; Zeev Nitsan; Shmuel Appel; Chen Hoffmann; Hanna Rosenmann; Esther Kahana; Hedok Lee
Journal:  J Neurol       Date:  2014-12-19       Impact factor: 4.849

5.  The Creutzfeldt-Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression.

Authors:  O S Cohen; I Prohovnik; A D Korczyn; L Ephraty; Z Nitsan; R Tsabari; S Appel; H Rosenmann; E Kahana; J Chapman
Journal:  Acta Neurol Scand       Date:  2011-02-08       Impact factor: 3.209

6.  An In Vivo 11C-(R)-PK11195 PET and In Vitro Pathology Study of Microglia Activation in Creutzfeldt-Jakob Disease.

Authors:  Leonardo Iaccarino; Rosa Maria Moresco; Luca Presotto; Orso Bugiani; Sandro Iannaccone; Giorgio Giaccone; Fabrizio Tagliavini; Daniela Perani
Journal:  Mol Neurobiol       Date:  2017-04-28       Impact factor: 5.590

7.  Putaminal volume and diffusion in early familial Creutzfeldt-Jakob disease.

Authors:  Ilana Seror; Hedok Lee; Oren S Cohen; Chen Hoffmann; Isak Prohovnik
Journal:  J Neurol Sci       Date:  2009-10-13       Impact factor: 3.181

8.  Cerebral white matter disruption in Creutzfeldt-Jakob disease.

Authors:  H Lee; O S Cohen; H Rosenmann; C Hoffmann; P B Kingsley; A D Korczyn; J Chapman; I Prohovnik
Journal:  AJNR Am J Neuroradiol       Date:  2012-05-10       Impact factor: 3.825

9.  Multiparameter MR imaging in the 6-OPRI variant of inherited prion disease.

Authors:  E De Vita; G R Ridgway; R I Scahill; D Caine; P Rudge; T A Yousry; S Mead; J Collinge; H R Jäger; J S Thornton; H Hyare
Journal:  AJNR Am J Neuroradiol       Date:  2013-03-28       Impact factor: 3.825

10.  White Matter Integrity Involvement in the Preclinical Stage of Familial Creutzfeldt-Jakob Disease: A Diffusion Tensor Imaging Study.

Authors:  Donglai Jing; Yaojing Chen; Kexin Xie; Yue Cui; Chunlei Cui; Li Liu; Hui Lu; Jing Ye; Ran Gao; Lin Wang; Zhigang Liang; Zhanjun Zhang; Liyong Wu
Journal:  Front Aging Neurosci       Date:  2021-05-19       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.